Duloxetine Hydrochloride (Cymbalta)

A thiophene derivative and selective NEUROTRANSMITTER UPTAKE INHIBITOR for SEROTONIN and NORADRENALINE (SNRI). It is an ANTIDEPRESSIVE AGENT and ANXIOLYTIC, and is also used for the treatment of pain in patients with DIABETES MELLITUS and FIBROMYALGIA.

Also Known As:

Cymbalta; Duloxetine; Duloxetine Ethanedioate (1:1), (+-)-isomer - T353987; Duloxetine HCl; Duloxetine, (+)-isomer; LY 227942; LY 248686; LY-227942; LY-248686; LY227942; N-methyl-3-(1-naphthalenyloxy)-2-thiophenepropanamine; N-methyl-3-(1-naphthalenyloxy)-3-(2-thiophene)propanamide; HCl, Duloxetine; Hydrochloride, Duloxetine; LY248686

Networked: 1669 relevant articles (437 outcomes, 561 trials/studies)

Relationship Network

Drug Context: Research Results

Experts

1.	Wohlreich, Madelaine M: 48 articles (03/2016 - 04/2004)
2.	Detke, Michael J: 37 articles (03/2011 - 01/2002)
3.	Raskin, Joel: 33 articles (01/2014 - 10/2003)
4.	Mallinckrodt, Craig H: 31 articles (07/2009 - 10/2003)
5.	Wang, Fujun: 24 articles (07/2012 - 06/2005)
6.	Desaiah, Durisala: 23 articles (01/2013 - 12/2005)
7.	Arnold, Lesley M: 22 articles (05/2019 - 09/2004)
8.	Watkin, John G: 22 articles (07/2009 - 04/2004)
9.	Chappell, Amy S: 20 articles (06/2011 - 03/2007)
10.	Kajdasz, Daniel K: 20 articles (06/2011 - 07/2005)

Related Diseases

1.	Pain (Aches) 10/01/2011 - "Quantifiable early improvement in pain during the first 2 weeks of treatment with duloxetine was highly predictive of response or nonresponse after 3 months of treatment. " 11/01/2011 - "Compared with patients on placebo, significantly more patients treated with duloxetine reported a moderately important pain reduction (≥30% reduction) in 9 of the 12 studies, a minimally important improvement in physical function in 8 of the 12 studies, and a moderately important to substantial improvement in Patient Global Impression of Improvement rating in 11 of the 12 studies. " 01/01/2007 - "The treatment with cymbalta resulted in significant reduction of pain in 90% patients, with full stopping of the syndrome in 10% and marked reduction in 55%. " 01/01/2021 - "In patients with ≥3 painful sites (57% of patients), pain reduction was significantly greater with duloxetine (n = 100) compared with placebo (n = 101) throughout the study (least squares mean change from baseline to Week 14: -2.68 vs -1.68). " 09/01/2015 - "Duloxetine-treated patients showed significantly greater pain relief compared with placebo-treated patients over the 12-week study period. "
2.	Major Depressive Disorder (Major Depressive Disorders) 11/01/2007 - "Duloxetine demonstrated superior efficacy in the treatment of major depressive disorder, when compared with placebo, regardless of the baseline severity of depressive symptoms, although effect sizes were largest in the most severely depressed patients." 01/01/2011 - "Efficacy of duloxetine on painful physical symptoms in major depressive disorder for patients with clinically significant painful physical symptoms at baseline: a meta-analysis of 11 double-blind, placebo-controlled clinical trials." 01/01/2011 - "To review efficacy of duloxetine for physical symptoms and depressive illness in patients with at least mild to moderate major depressive disorder (MDD; DSM-IV) and clinically significant painful physical symptoms at baseline. " 08/01/2007 - "This was a post hoc analysis to determine whether baseline severity of depression influenced the efficacy of duloxetine in treating major depressive disorder (MDD) and to better characterise the symptom response profile for duloxetine in patients with mild, moderate or more severe depression. " 01/01/2007 - "In placebo-controlled clinical trials, duloxetine has been shown to be effective and well-tolerated in patients with major depressive disorder (MDD). "
3.	Neuralgia (Stump Neuralgia) 02/01/2008 - "This UK-based economic model suggests that second-line use of duloxetine is a beneficial and cost-effective treatment strategy for diabetic peripheral neuropathic pain." 11/01/2010 - "Although the primary study endpoint was not achieved, the overall observed response pattern suggests the efficacy of duloxetine in the treatment of Chinese patients with diabetic peripheral neuropathic pain. " 10/24/2006 - "This study confirms previous findings that duloxetine at 60 mg QD and 60 mg BID is effective and safe in the management of diabetic peripheral neuropathic pain." 07/01/2005 - "Duloxetine at 60 and 120 mg/d was safe and effective in the management of diabetic peripheral neuropathic pain." 01/01/2009 - "Safety and efficacy of duloxetine in the treatment of diabetic peripheral neuropathic pain in older patients."
4.	Fibromyalgia (Fibrositis) 12/01/2010 - "To investigate the efficacy of flexible dose duloxetine 60-120 mg/day on changes in fibromyalgia (FM) symptoms assessed by the Patient Global Impression of Improvement (PGI-I) scale. " 05/01/2006 - "Duloxetine effective for fibromyalgia in some women." 07/01/2017 - "Duloxetine was safe and effective in the long-term treatment of Japanese patients with fibromyalgia." 09/01/2007 - "Duloxetine has been shown to be an effective and safe treatment for many of the symptoms associated with fibromyalgia, particularly for women. " 07/01/2017 - "We aimed to evaluate the long-term safety and efficacy of duloxetine 60 mg in Japanese patients with fibromyalgia enrolled from a preceding randomized, placebo-controlled, phase III duloxetine trial. "
5.	Stress Urinary Incontinence 02/06/2017 - "Although duloxetine is effective for stress urinary incontinence in women, the rates of associated harm were high when individual patient data were analyzed, and the harms outweighed the benefits." 07/01/2007 - "Duloxetine has been shown to be effective in women with stress urinary incontinence (SUI). " 12/01/2009 - "Duloxetine was found safe and effective in the treatment of moderate to severe female stress urinary incontinence (SUI) in controlled clinical trials; complementary data from routine clinical practice are still wanted. " 07/01/2008 - "To assess the maintenance of efficacy of duloxetine beyond 3 months, using data from several long-term, open-label studies, as the efficacy of duloxetine 40-mg twice daily for treating women with stress urinary incontinence (SUI) for up to 3 months has been established in several randomized, placebo-controlled clinical trials. " 07/01/2005 - "In clinical trials in women with stress urinary incontinence, duloxetine has demonstrated efficacy in reducing incontinence episodes and increasing quality of life with no serious adverse effects. "

Related Drugs and Biologics

1.	Serotonin (5 Hydroxytryptamine)
2.	Norepinephrine (Noradrenaline)
3.	Pregabalin (Lyrica)
4.	Antidepressive Agents (Antidepressants)
5.	Venlafaxine Hydrochloride (Effexor)
6.	Milnacipran (Ixel)
7.	Serotonin and Noradrenaline Reuptake Inhibitors
8.	Amitriptyline (Elavil)
9.	Gabapentin (Neurontin)
10.	Analgesics (Analgesic Drugs)

Related Therapies and Procedures

1.	Therapeutics
2.	Drug Therapy (Chemotherapy)
3.	Analgesia
4.	Prostatectomy (Retropubic Prostatectomy)
5.	Knee Replacement Arthroplasty (Total Knee Replacement)